A survey of severe asthma in Canada: results from the CASCADE practice reflective program

Krystelle Godbout, Harold Kim, Irvin Mayers, James Paterson, Charles K. N. Chan
{"title":"A survey of severe asthma in Canada: results from the CASCADE practice reflective program","authors":"Krystelle Godbout, Harold Kim, Irvin Mayers, James Paterson, Charles K. N. Chan","doi":"10.1186/s13223-024-00891-x","DOIUrl":null,"url":null,"abstract":"Since the last guidance was published by the Canadian Thoracic Society, there have been several advances in the clinical management of severe asthma. To gain a better understanding of the current standards of care and treatment patterns of patients, the CASCADE practice reflective program was established to conduct a real-world analysis of severe asthma management among specialists in Canada with a goal of identifying areas of opportunity to enhance patient management and outcomes. The CASCADE program was a two-part practice reflective and assessment program delivered through an on-line portal for selected specialists (Respirologists and Allergists) in Canada. The program consisted of a one-time overview survey of physician practice to establish overall practice parameters, followed by a review of at least 5 severe asthma patients to establish the current landscape of severe asthma management. The program collected practice overview surveys from 78 specialists (52 Respirologists, 24 Allergists, and 2 General practice physicians with an interest in respiratory disease) in 8 provinces. Practices included a variety of types in both large metropolitan centres and smaller regional settings. There were 503 patients reviewed and included in the program. Most (65%) patients were currently using a biologic treatment, 30% were biologic naive, and 5% had used a biologic treatment in the past. Most patients (53%) were reported to have mixed allergic and eosinophilic phenotypes, despite a perception that allergic, eosinophilic and mixed phenotypes were evenly balanced in the physician practice. Overall, patients currently treated with biologic agents had parameters suggesting higher control and were more satisfied with treatment. However, there was less than optimal treatment satisfaction for more than half of all patients, particularly for those patients not treated with a biologic agent. Phenotyping is hampered by poor availability for several assessments, and the full range of treatments are not currently fully utilized, partly due to physician familiarity with the agents and partly due to prescribing restrictions. Even when treated with biologic agents, patient satisfaction can still be improved.","PeriodicalId":501611,"journal":{"name":"Allergy, Asthma & Clinical Immunology","volume":"33 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Allergy, Asthma & Clinical Immunology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s13223-024-00891-x","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Since the last guidance was published by the Canadian Thoracic Society, there have been several advances in the clinical management of severe asthma. To gain a better understanding of the current standards of care and treatment patterns of patients, the CASCADE practice reflective program was established to conduct a real-world analysis of severe asthma management among specialists in Canada with a goal of identifying areas of opportunity to enhance patient management and outcomes. The CASCADE program was a two-part practice reflective and assessment program delivered through an on-line portal for selected specialists (Respirologists and Allergists) in Canada. The program consisted of a one-time overview survey of physician practice to establish overall practice parameters, followed by a review of at least 5 severe asthma patients to establish the current landscape of severe asthma management. The program collected practice overview surveys from 78 specialists (52 Respirologists, 24 Allergists, and 2 General practice physicians with an interest in respiratory disease) in 8 provinces. Practices included a variety of types in both large metropolitan centres and smaller regional settings. There were 503 patients reviewed and included in the program. Most (65%) patients were currently using a biologic treatment, 30% were biologic naive, and 5% had used a biologic treatment in the past. Most patients (53%) were reported to have mixed allergic and eosinophilic phenotypes, despite a perception that allergic, eosinophilic and mixed phenotypes were evenly balanced in the physician practice. Overall, patients currently treated with biologic agents had parameters suggesting higher control and were more satisfied with treatment. However, there was less than optimal treatment satisfaction for more than half of all patients, particularly for those patients not treated with a biologic agent. Phenotyping is hampered by poor availability for several assessments, and the full range of treatments are not currently fully utilized, partly due to physician familiarity with the agents and partly due to prescribing restrictions. Even when treated with biologic agents, patient satisfaction can still be improved.
加拿大严重哮喘调查:CASCADE 实践反思计划的结果
自加拿大胸科学会发布上一份指南以来,重症哮喘的临床治疗取得了多项进展。为了更好地了解目前的护理标准和患者的治疗模式,CASCADE 实践反思计划应运而生,该计划旨在对加拿大专科医生的重症哮喘管理进行实际分析,目的是找出有机会加强患者管理和提高治疗效果的领域。CASCADE 计划是一项由两部分组成的实践反思和评估计划,通过在线门户网站提供给加拿大的部分专科医生(哮喘病学家和过敏学家)。该计划包括对医生的临床实践进行一次性概述调查,以确定整体实践参数,然后对至少 5 名重症哮喘患者进行复查,以确定重症哮喘管理的现状。该计划收集了来自 8 个省 78 名专科医生(52 名哮喘专科医生、24 名过敏专科医生和 2 名呼吸系统疾病全科医生)的实践概况调查。这些医疗机构既有大都市中心的各种类型,也有较小的地区性医疗机构。共有 503 名患者接受了审查并被纳入该计划。大多数患者(65%)目前正在使用生物制剂治疗,30%尚未使用生物制剂,5%过去曾使用过生物制剂治疗。据报告,大多数患者(53%)具有过敏和嗜酸性粒细胞混合表型,尽管医生们认为过敏、嗜酸性粒细胞和混合表型的患者比例均衡。总体而言,目前接受生物制剂治疗的患者的各项指标均表明其病情得到了较好的控制,并且对治疗更加满意。然而,半数以上的患者对治疗的满意度并不理想,尤其是那些未接受生物制剂治疗的患者。表型分析因几种评估的可用性较差而受到阻碍,目前尚未充分利用所有治疗方法,部分原因是医生对药物不熟悉,部分原因是处方限制。即使使用生物制剂治疗,患者的满意度仍可提高。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信